<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37533043</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>02</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Sabin polio virus protein 1 (VP1) evolution in patients with acute flaccid paralysis from 2010 to 2016 in Uganda.</ArticleTitle><Pagination><StartPage>172</StartPage><MedlinePgn>172</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">172</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-023-02143-7</ELocationID><Abstract><AbstractText>Acute flaccid paralysis (AFP) is a rare side effect of the oral polio vaccine but can be associated with outbreaks and permanent disability in patients harboring circulating vaccine-derived polioviruses (cVDPVs). With the advancement of polio abolition in a glimpse, cVDPVs are causing outbreaks and slowing the polio eradication process. The polio virus protein 1 (VP1) contains the binding site that is key for virus transmission. Understanding the evolution of VP1 among AFP patients could yield more insight into the early events of cVDPVs. Polioviruses were identified from stool specimens of AFP patients using cell culture; and confirmed by the real time RT PCR intra-typic differentiation and vaccine-derived poliovirus assays. Seventy-nine (79) Sabin-like poliovirus 1 (SL1) and 86 Sabin-like poliovirus 3 (SL3) were sequenced. The VP1 amino acid substitutions T106A in Sabin poliovirus 1 and A54V in Sabin poliovirus 3 were common among the AFP patients as has been found in previous studies. Other substitutions that were associated with AFP were: T290A and A54T in SL1 and SL3 respectively. Nucleotide mutations that were common among the AFP patients included T402C, C670A, and T816C in SL1, and G22A, C375Y, A472R, and A694T in SL3 polioviruses. Characterizing mutations that are associated with AFP could contribute to efforts pursued to mitigate the risk of vaccine-derived polioviruses and promote development of safer vaccines.</AbstractText><CopyrightInformation>© 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nanteza</LastName><ForeName>Mary Bridget</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Uganda Virus Research Institute, Plot 51-59 Nakiwogo Road, P. O. Box 49, Entebbe, Uganda. marybridgetnanteza@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakamutumaho</LastName><ForeName>Barnabas</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Uganda Virus Research Institute, Plot 51-59 Nakiwogo Road, P. O. Box 49, Entebbe, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tushabe</LastName><ForeName>Phionah</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Uganda Virus Research Institute, Plot 51-59 Nakiwogo Road, P. O. Box 49, Entebbe, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Namuwulya</LastName><ForeName>Prossy</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Uganda Virus Research Institute, Plot 51-59 Nakiwogo Road, P. O. Box 49, Entebbe, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birungi</LastName><ForeName>Molly</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Uganda Virus Research Institute, Plot 51-59 Nakiwogo Road, P. O. Box 49, Entebbe, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhatemwa</LastName><ForeName>Rajab</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Uganda Virus Research Institute, Plot 51-59 Nakiwogo Road, P. O. Box 49, Entebbe, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eliku</LastName><ForeName>James Peter</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Uganda Virus Research Institute, Plot 51-59 Nakiwogo Road, P. O. Box 49, Entebbe, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tibanagwa</LastName><ForeName>Mayi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Uganda Virus Research Institute, Plot 51-59 Nakiwogo Road, P. O. Box 49, Entebbe, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakooza</LastName><ForeName>Proscovia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>WHO Country Office, P. O. Box 24578, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bukenya</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Uganda Virus Research Institute, Plot 51-59 Nakiwogo Road, P. O. Box 49, Entebbe, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bwogi</LastName><ForeName>Josephine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Uganda Virus Research Institute, Plot 51-59 Nakiwogo Road, P. O. Box 49, Entebbe, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byabamazima</LastName><ForeName>Charles Rutebarika</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>World Health Organization AFRO, East and Southern Africa (ESA), 82-86 Enterprise Road, Highlands, Belvedere, P. O. Box BE 773, Harare, Zimbabwe.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant><Grant><GrantID>MC_UU_00033/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000509">alpha-Fetoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000629404">acute flaccid myelitis</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014454" MajorTopicYN="N" Type="Geographic">Uganda</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000509" MajorTopicYN="N">alpha-Fetoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010243" MajorTopicYN="N">Paralysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute flaccid paralysis</Keyword><Keyword MajorTopicYN="N">Mutation</Keyword><Keyword MajorTopicYN="N">Sabin poliovirus</Keyword><Keyword MajorTopicYN="N">Uganda</Keyword><Keyword MajorTopicYN="N">VP1</Keyword><Keyword MajorTopicYN="N">Vaccine-derived polioviruses</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>3</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>2</Day><Hour>23</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37533043</ArticleId><ArticleId IdType="pmc">PMC10399017</ArticleId><ArticleId IdType="doi">10.1186/s12985-023-02143-7</ArticleId><ArticleId IdType="pii">10.1186/s12985-023-02143-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Racaniello VR. One hundred years of poliovirus pathogenesis. Virology. 2006;344:9–16. doi: 10.1016/j.virol.2005.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2005.09.015</ArticleId><ArticleId IdType="pubmed">16364730</ArticleId></ArticleIdList></Reference><Reference><Citation>Nomoto A. No title eradication of poliomyelitis. Nat Immunol. 2002;3(3):205–208. doi: 10.1038/ni0302-205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni0302-205</ArticleId><ArticleId IdType="pubmed">11875454</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew OM, Mulders MN, Lipskaya GY, da Silva EE, Patlansch MA. Molecular epidemiology of polioviruses. Semin Virol. 1995;6(6):401–414. doi: 10.1016/S1044-5773(05)80017-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1044-5773(05)80017-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Ma T, Liu J, Zhao X, Cheng Z, Guo H, et al. Bioinformatics analysis and genetic diversity of the poliovirus. J Med Microbiol. 2014;63:1724–1731. doi: 10.1099/jmm.0.081992-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jmm.0.081992-0</ArticleId><ArticleId IdType="pubmed">25261065</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkegaard K. Mutations in VP1 of poliovirus specifically affect both encapsidation and release of viral RNA. J Virol. 1990;64(1):195–206. doi: 10.1128/jvi.64.1.195-206.1990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.64.1.195-206.1990</ArticleId><ArticleId IdType="pmc">PMC249083</ArticleId><ArticleId IdType="pubmed">2152812</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw J, Jorba J, Zhao K, Iber J, Chen Q, Adu F, et al. Dynamics of evolution of poliovirus neutralizing antigenic sites and other capsid functional domains during a large and prolonged outbreak. J Virol. 2018;92(9):10–1128. doi: 10.1128/JVI.01949-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01949-17</ArticleId><ArticleId IdType="pmc">PMC5899205</ArticleId><ArticleId IdType="pubmed">29444940</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Fischer ER, Kouiavskai D, Hansen BT, Ludtke SJ, Bidzhieva B, et al. Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor. Proc Natl Acad Sci U S A. 2013;110(50):20242–20247. doi: 10.1073/pnas.1320041110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1320041110</ArticleId><ArticleId IdType="pmc">PMC3864303</ArticleId><ArticleId IdType="pubmed">24277851</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorba J, Campagnoli R, De L, Kew O. Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. J Virol. 2008;82(9):4429–4440. doi: 10.1128/JVI.02354-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02354-07</ArticleId><ArticleId IdType="pmc">PMC2293050</ArticleId><ArticleId IdType="pubmed">18287242</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew OM, Sutter RW, De Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Ann Rev Microbiol. 2005;59:587–635. doi: 10.1146/annurev.micro.58.030603.123625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.micro.58.030603.123625</ArticleId><ArticleId IdType="pubmed">16153180</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward CD, Flanegan JB. Determination of the poliovirus RNA polymerase error frequency at eight sites in the viral genome. J Virol. 1992;66(6):3784–3793. doi: 10.1128/jvi.66.6.3784-3793.1992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.66.6.3784-3793.1992</ArticleId><ArticleId IdType="pmc">PMC241164</ArticleId><ArticleId IdType="pubmed">1316481</ArticleId></ArticleIdList></Reference><Reference><Citation>De la Torre JC, Giachetti C, Semler BL, Holland JJ. High frequency of single-base transitions and extreme frequency of precise multiple-base reversion mutations in poliovirus. Proc Natl Acad Sci U S A. 1992;89(7):2531–2535. doi: 10.1073/pnas.89.7.2531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.89.7.2531</ArticleId><ArticleId IdType="pmc">PMC48695</ArticleId><ArticleId IdType="pubmed">1313561</ArticleId></ArticleIdList></Reference><Reference><Citation>Famulare M, Chang S, Iber J, Zhao K, Adeniji JA, Bukbuk D, et al. Sabin vaccine reversion in the field: a comprehensive analysis of sabin-like poliovirus isolates in Nigeria. J Virol. 2016;90(1):317–331. doi: 10.1128/JVI.01532-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01532-15</ArticleId><ArticleId IdType="pmc">PMC4702576</ArticleId><ArticleId IdType="pubmed">26468545</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor PD, John A, Ferguson M, Icenogle JP. Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee. J Gen Virol. 1986;67(4):693–706. doi: 10.1099/0022-1317-67-4-693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-67-4-693</ArticleId><ArticleId IdType="pubmed">2420925</ArticleId></ArticleIdList></Reference><Reference><Citation>Valesano AL, Taniuchi M, Fitzsimmons WJ, Islam MO, Ahmed T, Zaman K, et al. The early evolution of oral poliovirus vaccine is shaped by strong positive selection and tight transmission bottlenecks. Cell Host Microbe. 2021;29(1):32–43. doi: 10.1016/j.chom.2020.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.10.011</ArticleId><ArticleId IdType="pmc">PMC7815045</ArticleId><ArticleId IdType="pubmed">33212020</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgensen D, Pons-Salort M, Shaw AG, Grassly NC. The role of genetic sequencing and analysis in the polio eradication programme. Virus Evol. 2020;6(2):veaa040. doi: 10.1093/ve/veaa040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ve/veaa040</ArticleId><ArticleId IdType="pmc">PMC7409915</ArticleId><ArticleId IdType="pubmed">32782825</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong W, Gauld J, Famulare M. From vaccine to pathogen: modelling sabin 2 vaccine virus reversion and evolutionary epidemiology. 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10491863</ArticleId><ArticleId IdType="pubmed">37692896</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan DM, Zhang Y, Wang DY. Analysis of 4 clustered high risk acute flaccid paralysis cases in Shanxi Province in 2006. Zhongguo ji = hua mian yi Chin J Vacc Immun. 2010;16(2):127–131.</Citation><ArticleIdList><ArticleId IdType="pubmed">20575263</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimi P, Tabatabaie H, Gouya MM, Zahraie M, Mahmudi M, Ziaie A, et al. Characterization of mutations in the VP(1) region of Sabin strain type 1 polioviruses isolated from vaccine-associated paralytic poliomyelitis cases in Iran. J Clin Virol. 2007;39(4):304–307. doi: 10.1016/j.jcv.2007.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2007.04.017</ArticleId><ArticleId IdType="pubmed">17590391</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor PD. The molecular biology of poliovaccines. J Gen Virol. 1992;73:3065–3077. doi: 10.1099/0022-1317-73-12-3065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-73-12-3065</ArticleId><ArticleId IdType="pubmed">1335021</ArticleId></ArticleIdList></Reference><Reference><Citation>De Melo Cassemiro KMS, Burlandy FM, Barbosa MRF, Chen Q, Jorba J, Hachich EM, et al. Molecular and phenotypic characterization of a highly evolved type 2 vaccine-derived poliovirus isolated from seawater in Brazil, 2014. PLoS ONE. 2016;11(3):e0152251. doi: 10.1371/journal.pone.0152251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0152251</ArticleId><ArticleId IdType="pmc">PMC4809597</ArticleId><ArticleId IdType="pubmed">27019095</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization(WHO). Classification and reporting of vaccine-derived polioviruses (VDPV) GPEI guidelines. 2016; http://polioeradication.org/wp-content/uploads/2016/09/Reporting-and-Classification-of-VDPVs_Aug2016_EN.pdf</Citation></Reference><Reference><Citation>World Health Organization. Polio Laboratory Manual [Internet]. 4th ed. 2004. https://apps.who.int/iris/handle/10665/68762</Citation></Reference><Reference><Citation>Kilpatrick DR, Ching K, Iber J, Chen Q, Yang SJ, De L, et al. Identification of vaccine-derived polioviruses using dual-stage real-time RT-PCR. J Virol Meth. 2014;197:25–28. doi: 10.1016/j.jviromet.2013.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2013.11.017</ArticleId><ArticleId IdType="pmc">PMC8215842</ArticleId><ArticleId IdType="pubmed">24321704</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol. 2016;33(7):1870–1874. doi: 10.1093/molbev/msw054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/molbev/msw054</ArticleId><ArticleId IdType="pmc">PMC8210823</ArticleId><ArticleId IdType="pubmed">27004904</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew O, Morris-Glasgow V, Landaverde M, Burns C, Shaw J, Garib Z, et al. Outbreak of poliomyelitis in hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science (80-) 2002;296(5566):356–359. doi: 10.1126/science.1068284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1068284</ArticleId><ArticleId IdType="pubmed">11896235</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeuh-Mba SA, Kavunga-Membo H, Joffret ML, Yogolelo R, Endegue-Zanga MC, Bessaud M, et al. Genetic landscape and macro-evolution of cocirculating coxsackieviruses A and vaccinederived polioviruses in the democratic Republic of Congo, 2008–2013. PLoS Negl Trop Dis. 2019;13(4):e0007335. doi: 10.1371/journal.pntd.0007335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0007335</ArticleId><ArticleId IdType="pmc">PMC6505894</ArticleId><ArticleId IdType="pubmed">31002713</ArticleId></ArticleIdList></Reference><Reference><Citation>Unpublished data. Aggregated Country Data for AFP Surveillance, Uganda National Expanded Programme on Immunisation/Ministry of Health, Uganda.</Citation></Reference><Reference><Citation>WHO and UNICEF. Uganda: WHO and UNICEF estimates of Immunization coverage: 2019 revision [Internet]. 2019 https://www.who.int/immunization/monitoring_surveillance/data/uga.pdf. Accessed 15 Sept 2021</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>